| scholarly article | Q13442814 |
| P50 | author | Claudine Isaacs | Q90579511 |
| P2093 | author name string | Beth N Peshkin | |
| Marc D Schwartz | |||
| Kristi D Graves | |||
| Suzanne C O'Neill | |||
| Elizabeth Spellman | |||
| Nadiyah Sulayman | |||
| P2860 | cites work | Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. | Q50980792 |
| Psychological side effects of breast cancer screening. | Q51163476 | ||
| Involvement in decision-making and breast cancer survivor quality of life. | Q51872344 | ||
| Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. | Q53603230 | ||
| Information needs and decisional preferences in women with breast cancer | Q73328389 | ||
| Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? | Q82030079 | ||
| Patients' preferred and retrospectively perceived levels of involvement during decision-making regarding carpal tunnel release | Q83146771 | ||
| Taking shared decision making more seriously | Q83538694 | ||
| Shared decision making: prostate cancer patients' appraisal of treatment alternatives and oncologists' eliciting and responding behavior, an explorative study | Q84320043 | ||
| Evidence Based Medicine and Shared Decision Making: the challenge of getting both evidence and preferences into health care | Q37290671 | ||
| Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm. | Q37305722 | ||
| Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients | Q37378572 | ||
| Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer | Q37476651 | ||
| Women's experiences with genomic testing for breast cancer recurrence risk | Q37705187 | ||
| Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer | Q37871407 | ||
| Impact of Event Scale: A Measure of Subjective Stress | Q39513124 | ||
| Preferences for treatment control among adults with cancer | Q41415892 | ||
| A decision aid to assist in adjuvant therapy choices for breast cancer | Q42681645 | ||
| Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study | Q43138098 | ||
| Meeting the decision-making preferences of patients with breast cancer in oncology consultations: impact on decision-related outcomes | Q44972981 | ||
| The influence of a gene expression profile on breast cancer decisions | Q46127572 | ||
| Patient involvement in surgery treatment decisions for breast cancer. | Q48477511 | ||
| Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. | Q49157801 | ||
| The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. | Q50114287 | ||
| Cancer genetic risk assessment for individuals at risk of familial breast cancer | Q24203650 | ||
| Quality of life among younger women with breast cancer | Q30150819 | ||
| Sharing decisions in cancer care | Q30667711 | ||
| Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer | Q31960178 | ||
| American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer | Q33303529 | ||
| Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review | Q33594181 | ||
| Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20 | Q33770332 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Communicating genetic and genomic information: health literacy and numeracy considerations | Q34017520 | ||
| Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection | Q34092182 | ||
| Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. | Q34190743 | ||
| Validation of a decisional conflict scale | Q34321486 | ||
| Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer | Q34337362 | ||
| Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer | Q34638067 | ||
| Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes | Q34944244 | ||
| Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis | Q35634237 | ||
| Decision making about surgery for early-stage breast cancer | Q35668341 | ||
| Factors associated with patient involvement in surgical treatment decision making for breast cancer | Q35728401 | ||
| Advances in breast cancer: pathways to personalized medicine | Q35951346 | ||
| Treatment decision-making for localized prostate cancer: what younger men choose and why. | Q36182162 | ||
| Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results | Q36433719 | ||
| Decision aids and breast cancer: do they influence choice for surgery and knowledge of treatment options? | Q36763468 | ||
| Development of the 21-gene assay and its application in clinical practice and clinical trials | Q37079600 | ||
| Improving communication of breast cancer recurrence risk | Q37124483 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | quality of life | Q13100823 |
| P304 | page(s) | 728290 | |
| P577 | publication date | 2012-07-30 | |
| P1433 | published in | Journal of cancer epidemiology | Q27722863 |
| P1476 | title | Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS. | |
| P478 | volume | 2012 |
| Q34777432 | Association between genomic recurrence risk and well-being among breast cancer patients |
| Q28083844 | Clinicians' expectations for gene-driven cancer therapy |
| Q34551573 | Engaging in health behaviors to lower risk for breast cancer recurrence |
| Q92532687 | Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial |
| Q63198469 | Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review |
| Q38383042 | Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer? |
| Q57282983 | The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations |
| Q37586558 | Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results |
Search more.